Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Insider Timothy Hoey Sells 1,353 Shares

Tenaya Therapeutics, Inc. (NASDAQ:TNYAGet Rating) insider Timothy Hoey sold 1,353 shares of the company’s stock in a transaction on Tuesday, April 26th. The shares were sold at an average price of $10.13, for a total transaction of $13,705.89. Following the completion of the sale, the insider now directly owns 198,646 shares of the company’s stock, valued at approximately $2,012,283.98. The sale was disclosed in a filing with the SEC, which is accessible through this link.

NASDAQ:TNYA opened at $9.86 on Friday. The company has a fifty day moving average of $11.67 and a 200 day moving average of $15.92. Tenaya Therapeutics, Inc. has a 52 week low of $8.82 and a 52 week high of $32.00.

Tenaya Therapeutics (NASDAQ:TNYAGet Rating) last posted its quarterly earnings results on Wednesday, March 23rd. The company reported ($0.63) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.57) by ($0.06). Equities research analysts expect that Tenaya Therapeutics, Inc. will post -2.78 EPS for the current fiscal year.

A number of large investors have recently bought and sold shares of TNYA. SG Americas Securities LLC bought a new stake in Tenaya Therapeutics during the 3rd quarter valued at $129,000. New York State Common Retirement Fund bought a new position in Tenaya Therapeutics in the 3rd quarter worth $50,000. Deutsche Bank AG bought a new position in Tenaya Therapeutics in the 3rd quarter worth $166,000. TD Asset Management Inc. bought a new position in Tenaya Therapeutics in the 3rd quarter worth $626,000. Finally, BlackRock Inc. bought a new position in Tenaya Therapeutics in the 3rd quarter worth $33,448,000. Institutional investors own 79.94% of the company’s stock.

A number of equities research analysts have recently issued reports on the stock. Zacks Investment Research cut shares of Tenaya Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, January 13th. Chardan Capital reaffirmed a “buy” rating on shares of Tenaya Therapeutics in a research note on Monday, January 17th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Buy” and an average target price of $30.50.

About Tenaya Therapeutics (Get Rating)

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hypertrophic cardiomyopathy (gHCM) caused by haploinsufficient myosin binding protein C3 (MYBPC3) gene mutations; and TN-301, a small molecule inhibitor of histone deacetylase 6 (HDAC6i) for use in heart failure with preserved ejection fraction (HFpEF) and genetic dilated cardiomyopathy (gDCM).

Recommended Stories

Receive News & Ratings for Tenaya Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenaya Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.